Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

<p>Abstract</p> <p>Background</p> <p>Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC). Few treatment options are available for NSCLC patients who have...

Full description

Bibliographic Details
Main Authors: Baba Junko, Koshio Jun, Ichikawa Kosuke, Kagamu Hiroshi, Tanaka Hiroshi, Kondo Rie, Ota Takeshi, Tanaka Junta, Watanabe Satoshi, Miyabayashi Takao, Narita Ichiei, Yoshizawa Hirohisa
Format: Article
Language:English
Published: BMC 2011-01-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/11/1

Internet

http://www.biomedcentral.com/1471-2407/11/1

Similar Items